![](\"https:\/\/mms.businesswire.com\/media\/20260529023394\/en\/2817966\/5\/113350.jpg\")
<\/a><\/a>\nBy integrating clinical and commercial intelligence into R&D, the solution enables pharmaceutical and biotech organizations to make earlier and more informed decisions across portfolio, strategy, trial design, evidence generation, and go-to-market planning \u2014 while in early clinical development.<\/p>
\nUnlike traditional competitive intelligence approaches that rely on retrospective analysis of media and historical market activity, QuantHealth\u2019s solution predicts both clinical trial-level results and sub-population-level results in order to build the future positioning map. This solution predicts the performance of competitive assets that are still in R&D and in-market, without any sponsor data. It then provides actionable insights for clinical development teams to refine the target patient population and make big-picture decisions related to clinical trial design and capital deployments.<\/p>
\nThe launch comes when the pharmaceutical industry faces growing pressure to improve development efficiency and commercial execution<\/a>. Less than 10% of drug candidates ultimately receive regulatory approval, while more than one-third of launched medicines fail to meet commercial expectations, often due to poor market differentiation, inadequate understanding of patient and physician needs, and ineffective launch positioning<\/a>.<\/p> \n\u201cClinical development teams have historically separated R&D and commercial decision-making, often addressing go-to-market strategy too late in the process. QuantHealth is bridging the gap between R&D and commercial teams by bringing predictive competitor intelligence directly into clinical development, enabling organizations to evaluate the probability of trial success, but also future market positioning and commercial potential earlier,\u201d said Orr Inbar, CEO and co-founder of QuantHealth.<\/p> \n\u201cToo often, clinical development teams have had to make critical decisions based on historical performance from similar drugs. But in today\u2019s rapidly evolving landscape\u2013with growing complexity and new therapeutic categories emerging\u2013looking in the rearview mirror is no longer enough,\u201d says Inbar.<\/p> \nThe solution\u2019s core capabilities are already being used by three of the world\u2019s top 20 pharmaceutical companies across competitive intelligence, clinical development, and commercial strategy teams.<\/p> \nThe platform operates as a continuously self-optimizing system that combines purpose-built autonomous AI agents, news and market intelligence, and the industry\u2019s only clinical trial foundation model trained on more than 100 million patient records and validated across more than 600 completed clinical trials.<\/p> \nBy enabling organizations to simulate market dynamics while therapies are still in development, QuantHealth aims to help life sciences companies reduce development risk, prioritize high-potential assets, improve launch readiness, and maximize long-term commercial success. To learn more, visit https:\/\/quanthealth.ai\/<\/a>.<\/p> \nAbout QuantHealth<\/b><\/p> \nQuantHealth is the global leader for AI clinical trial simulation, bringing together the industry\u2019s most advanced clinical trial simulations portfolio \u2014 600+ trial simulations across 30 diseases with up to 90% prediction accuracy \u2014 and the category's largest real-world data set to help life sciences and biotechnology organizations improve the potential of clinical trial successes. QuantHealth solutions use real-world data and predictive modeling to simulate trials at scale, optimize protocols, reduce risk, and accelerate timelines. The company is a trusted partner for twelve of the top 20 global pharmaceutical companies.<\/p>